- Coordinator
- Universidad De Santiago De Compostela, Spain
- Runs
- 1 June 2022 to 31 May 2027
- Status
- Running
- EU funding
- €6.0m
- Total cost
- €6.0m
- Partners
- 20 organisations in 10 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101057367
What the project is doing
In the project's own words, from its summary on CORDIS.
More than 50% of cancer patients develop pain before death: 80% can be treated with drugs, but 20% show a low response or have serious adverse effects. Although non-pharmacological interventions such as neurosurgical procedures have been tested, these alternatives are not a preferred option to treat cancer pain due to their high cost, risk, invasiveness and not always proven efficacy. PAINLESS addresses a core component of pain relief, by using an innovative, evidence-based approach.
The objective is to adapt and implement a novel, cost-effective, home-based intervention based on neuromodulation to reduce pain and improve quality of life of cancer patients with chronic pain. On the assumption that treatment of chronic pain can benefit from research on the brain mechanisms of pain, we will first attempt to improve our understanding of the role of central pain modulation. The project will be organized in 3 studies: 1) A cohort, longitudinal study (n=450) to explore whether the biomarkers of central pain modulation mechanisms can be predictive of the future occurrence of chronic pain in cancer patients; 2) A cross-sectional study to characterize and stratify cancer patients with vs. without chronic pain (750 patients with the proposed biomarkers and taking into account a number of moderator variables); 3) A pilot study (n=450) to assess the feasibility an efficacy of at-home delivery of transcranial low intensity electric stimulation (tES) for the palliative care of cancer patients suffering from painPAINLESS will develop a customized web portal to share knowledge and to improve management of the patients; perform techno-economic analyses and Health Technology Assessment of the solution; analyze the possibilities of implementation in different European healthcare systems and results exploitation; and undertake an ambitious dissemination and communication strategy.
We will also propose a wide range of measures to ensure compliance with the highest ethical standars.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universidad De Santiago De Compostela | Santiago De Compostela | Spain | Coordinator |
| Association Europeenne Des Ligues Contre Le Cancer ASBL | Bruxelles / Brussel | Belgium | Participant |
| European Association for Palliative Care | Vilvoorde | Belgium | Participant |
| European Cancer Patient Coalition | Bruxelles / Brussel | Belgium | Participant |
| Ente Ospedaliero Cantonale | Bellinzona | Switzerland | Associatedpartner |
| Betthera Sro | Hradec Kralove | Czechia | Participant |
| Fakultni Nemocnice Hradec Kralove | Hradec Kralove | Czechia | Participant |
| Mentalab GmbH | Munich | Germany | Participant |
| Neuroconn GmbH | Ilmenau | Germany | Participant |
| Universitaetsmedizin Goettingen - Georg-August-Universitaet Goettingen - Stiftung Oeffentlichen Rechts | Goettingen | Germany | Participant |
| Aalborg Universitet | Aalborg | Denmark | Participant |
| Fundacion Publica Galega De Investigacion Biomedica Galicia Sur | Vigo | Spain | Third party |
| Fundacion Publica Galega Instituto De Investigacion Sanitaria De Santiago De Compostela | Santiago De Compostela | Spain | Third party |
| Servizo Galego De Saude | Santiago De Compostela | Spain | Participant |
| Qst Lab | Strasbourg | France | Participant |
| Technion - Israel Institute of Technology | Haifa | Israel | Participant |
| Instituto Portugues De Oncologia Do Porto Francisco Gentil, Epe | Porto | Portugal | Participant |
| Fundatia Hospice Casa Sperantei | Brasov | Romania | Participant |
| Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti | Bucharest | Romania | Participant |
| Software Imagination and Vision SRL | Bucuresti | Romania | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI